CorMedix secures supply deal for DefenCath with dialysis provider By Investing.com

BERKELEY HEIGHTS, N.J. – CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company, has announced a significant commercial supply agreement for its FDA-approved product, DefenCath® (taurolidine and heparin), with a leading midsize dialysis provider. The multi-year contract will extend the reach of DefenCath to over 500 dialysis facilities across the nation.

The product, which received FDA approval on November 15, 2023, under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), has been available in inpatient settings since April 15th and is expected to be released in outpatient dialysis clinics starting in July.

Joseph Todisco, CEO of CorMedix, expressed satisfaction with the progress in discussions with outpatient dialysis providers and emphasized the importance of the agreement in providing access to DefenCath for thousands of patients at risk of catheter-related bloodstream infections. He highlighted the company’s commitment to ensuring broad access to this infection prevention product.

DefenCath is positioned as a key product in CorMedix’s portfolio, with the company planning to expand its use as a catheter lock solution for additional patient populations. This latest agreement aligns with CorMedix’s focus on developing and commercializing therapeutic products aimed at preventing and treating life-threatening conditions and diseases.

This news is based on a press release statement from CorMedix Inc. and reflects the company’s strategic steps to solidify its presence in the healthcare market, particularly in the area of infection control within dialysis settings.

InvestingPro Insights

As CorMedix Inc. (NASDAQ: CRMD) forges ahead with its commercial endeavors, the company’s financial health and market performance offer insights into its potential trajectory. According to InvestingPro data, CorMedix currently holds a market capitalization of $281.39 million USD. This valuation comes in the context of a challenging financial landscape for the company, with a negative P/E ratio of -5.46, reflecting investor concerns over profitability. The company’s recent performance has shown a remarkable return over the last three months, with a 44.63% price total return, indicating a strong investor confidence following the FDA approval of DefenCath.

An InvestingPro Tip highlights that CorMedix holds more cash than debt on its balance sheet, which is a positive sign of the company’s liquidity and may provide some comfort to investors about its ability to fund ongoing operations and expansion efforts. However, another tip points out that the company is quickly burning through cash, which could raise questions about its long-term financial sustainability, especially as it has not been profitable over the last twelve months.

For those looking for deeper analysis, InvestingPro offers additional tips on CorMedix, including observations on the company’s weak gross profit margins and the volatile nature of its stock price movements. Subscribers can access these insights to better understand the risks and opportunities associated with investing in CorMedix. To explore these additional tips and gain a comprehensive view of CorMedix’s financial outlook, visit https://www.investing.com/pro/CRMD. Remember to use coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.